Literature DB >> 17537873

ABCG2 (breast cancer resistance protein/mitoxantrone resistance-associated protein) ATPase assay: a useful tool to detect drug-transporter interactions.

Hristos Glavinas1, Emese Kis, Akos Pál, Rita Kovács, Márton Jani, Erika Vági, Eva Molnár, Száva Bánsághi, Zoltán Kele, Tamás Janáky, György Báthori, Oliver von Richter, Gerrit-Jan Koomen, Péter Krajcsi.   

Abstract

The ATPase assay using membrane preparations from recombinant baculovirus-infected Spodoptera frugiperda ovarian (Sf9) cells is widely used to detect the interaction of compounds with different ATP-binding cassette transporters. However, Sf9 membrane preparations containing the wild-type ABCG2 transporter show an elevated baseline vanadate-sensitive ATPase activity, which cannot be further stimulated by substrates of ABCG2. Therefore, this assay system cannot be used for the detection of ABCG2 substrates. To overcome this difficulty we 1) purified membranes from a selected human cell line expressing wild-type ABCG2, and 2) inhibited the baseline ATPase activity with different inhibitors. In our modified assay, ABCG2 substrates were able to stimulate the baseline ATPase activity of ABCG2 expressed in membranes of human cells. Furthermore, using the specific ABCG2 inhibitors Ko143 or Ko134 allowed us to suppress the baseline vanadate-sensitive ATPase activity. Substrates of ABCG2 could stimulate this suppressed baseline ATPase, resulting in a better signal-to-background ratio and a robust assay to detect substrates of the ABCG2 transporter. The ATPase assay and the direct vesicular transport measurements for estrone-3-sulfate were in good accordance.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17537873     DOI: 10.1124/dmd.106.014605

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  16 in total

1.  A high-content assay strategy for the identification and profiling of ABCG2 modulators in live cells.

Authors:  Christophe Antczak; Boyoung Wee; Constantin Radu; Bhavneet Bhinder; Eric C Holland; Hakim Djaballah
Journal:  Assay Drug Dev Technol       Date:  2013-08-30       Impact factor: 1.738

2.  Recombinant synthesis of human ABCG2 expressed in the yeast Saccharomyces cerevisiae: an experimental methodological study.

Authors:  Anna Jacobs; Dana Emmert; Svenja Wieschrath; Christine A Hrycyna; Michael Wiese
Journal:  Protein J       Date:  2011-03       Impact factor: 2.371

Review 3.  Interaction of Isoflavones with the BCRP/ABCG2 Drug Transporter.

Authors:  Kristin M Bircsak; Lauren M Aleksunes
Journal:  Curr Drug Metab       Date:  2015       Impact factor: 3.731

Review 4.  ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development.

Authors:  Young Hee Choi; Ai-Ming Yu
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

Review 5.  Structure and function of the human breast cancer resistance protein (BCRP/ABCG2).

Authors:  Zhanglin Ni; Zsolt Bikadi; Mark F Rosenberg; Qingcheng Mao
Journal:  Curr Drug Metab       Date:  2010-09       Impact factor: 3.731

6.  The human breast cancer resistance protein (BCRP/ABCG2) shows conformational changes with mitoxantrone.

Authors:  Mark F Rosenberg; Zsolt Bikadi; Janice Chan; Xiaoping Liu; Zhanglin Ni; Xiaokun Cai; Robert C Ford; Qingcheng Mao
Journal:  Structure       Date:  2010-03-14       Impact factor: 5.006

7.  The anthelmintic triclabendazole and its metabolites inhibit the membrane transporter ABCG2/BCRP.

Authors:  Borja Barrera; Jon A Otero; Estefanía Egido; Julio G Prieto; Anna Seelig; Ana I Álvarez; Gracia Merino
Journal:  Antimicrob Agents Chemother       Date:  2012-04-16       Impact factor: 5.191

8.  Phase-II metabolism limits the antiproliferative activity of urolithins in human colon cancer cells.

Authors:  Antonio González-Sarrías; Juan Antonio Giménez-Bastida; María Ángeles Núñez-Sánchez; Mar Larrosa; María Teresa García-Conesa; Francisco A Tomás-Barberán; Juan Carlos Espín
Journal:  Eur J Nutr       Date:  2014-04       Impact factor: 5.614

9.  Synthetic Analogs of Curcumin Modulate the Function of Multidrug Resistance-Linked ATP-Binding Cassette Transporter ABCG2.

Authors:  Megumi Murakami; Shinobu Ohnuma; Michihiro Fukuda; Eduardo E Chufan; Katsuyoshi Kudoh; Keigo Kanehara; Norihiko Sugisawa; Masaharu Ishida; Takeshi Naitoh; Hiroyuki Shibata; Yoshiharu Iwabuchi; Suresh V Ambudkar; Michiaki Unno
Journal:  Drug Metab Dispos       Date:  2017-09-13       Impact factor: 3.922

10.  Tyrosine kinase inhibitors potentiate the cytotoxicity of MDR-substrate anticancer agents independent of growth factor receptor status in lung cancer cell lines.

Authors:  D M Collins; J Crown; N O'Donovan; A Devery; F O'Sullivan; L O'Driscoll; M Clynes; R O'Connor
Journal:  Invest New Drugs       Date:  2009-06-05       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.